SCHEMBL3601138

SCHEMBL3601138

O=C(Cl)c1cc(OCc2ccc(C(=O)c3ccccc3)cc2)cc(OCc2ccc(C(=O)c3ccccc3)cc2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A2 P31213 2/20 0.62
ALDH1A1 P00352 3/20 0.61
HTT P42858 2/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
MEN1 O00255 1/20 0.60
KMT2A Q03164 1/20 0.60
MAPT P10636 2/20 0.58
GAA P10253 1/20 0.58
RAB9A P51151 1/20 0.58
PPARG P37231 2/20 0.54
NR4A2 P43354 4/20 0.54
ATM Q13315 1/20 0.54
MAOB P27338 2/20 0.51
GLRA1 P23415 1/20 0.50
NR4A1 P22736 1/20 0.50
NR4A3 Q92570 1/20 0.50
SMPD1 P17405 2/20 0.49
RXRA P19793 1/20 0.49
RXRB P28702 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1795022 0.89 MEN1 (0.75) SRD5A2ALDH1A1MEN1KMT2ANR4A2
SCHEMBL3599480 0.88 MEN1 (0.79) SRD5A2ALDH1A1HTTSMN1; SMN2L3MBTL1
SCHEMBL26574732 0.86 MEN1 (0.70) SRD5A2ALDH1A1MEN1KMT2ANR4A2
SCHEMBL14533430 0.85 PARP10 (0.63) SRD5A2ALDH1A1HTTSMN1; SMN2L3MBTL1
SCHEMBL3592344 0.83 SMN1; SMN2 (0.62) SRD5A2ALDH1A1HTTSMN1; SMN2L3MBTL1
SCHEMBL339690 0.82 MEN1 (0.65) SRD5A2HTTSMN1; SMN2L3MBTL1MEN1
SCHEMBL19074331 0.82 ALDH1A1 (0.60) SRD5A2ALDH1A1HTTSMN1; SMN2L3MBTL1
SCHEMBL16137683 0.81 MEN1 (0.62) SRD5A2MEN1KMT2ARAB9ANR4A2
SCHEMBL30412560 0.80 NR4A2 (0.77) SRD5A2ALDH1A1MEN1KMT2ANR4A2
SCHEMBL340107 0.80 NR4A2 (0.77) SRD5A2ALDH1A1MEN1KMT2ANR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1141385-B1 TARGET MOLECULE ATTACHMENT TO SURFACES SURMODICS INC (US) 2017-07-05 EP disclosed
US-7691787-B2 Target molecule attachment to surfaces SURMODICS, INC. (US) 2010-04-06 US disclosed
US-20070104757-A1 LATENT REACTIVE BLOOD COMPATIBLE AGENTS Surmodics Coatings, LLC 2007-05-10 US disclosed
US-20070082022-A1 LATENT REACTIVE BLOOD COMPATIBLE AGENTS Surmodics Coatings, LLC 2007-04-12 US disclosed
US-7144573-B2 Latent reactive blood compatible agents SURMODICS, INC. (US) 2006-12-05 US disclosed
US-7071235-B2 Latent reactive blood compatible agents SURMODICS, INC. (US) 2006-07-04 US disclosed
EP-1069916-B1 LATENT REACTIVE BLOOD COMPATIBLE AGENTS SURMODICS INC (US) 2006-05-10 EP disclosed
US-20060052460-A1 Latent reactive blood compatible agents Surmodics Coatings, LLC 2006-03-09 US disclosed
US-20050170427-A1 Target molecule attachment to surfaces SURMODICS, INC. (US) 2005-08-04 US disclosed
EP-1019424-B1 REAGENT AND METHOD FOR ATTACHING TARGET MOLECULES TO A SURFACE SURMODICS INC (US) 2005-01-12 EP disclosed
EP-0888389-A4 PHOTOACTIVATABLE CHAIN TRANSFER AGENTS SURMODICS INC (US) 2001-03-14 EP disclosed
EP-1069916-A2 LATENT REACTIVE BLOOD COMPATIBLE AGENTS SurModics, Inc. (US) 2001-01-24 EP disclosed
EP-1019424-A2 REAGENT AND METHOD FOR ATTACHING TARGET MOLECULES TO A SURFACE SurModics, Inc. (US) 2000-07-19 EP disclosed
WO-2000040593-A2 TARGET MOLECULE ATTACHMENT TO SURFACES SURMODICS, INC. (US) 2000-07-13 WO disclosed
WO-1999047176-A2 LATENT REACTIVE BLOOD COMPATIBLE AGENTS SURMODICS, INC. (US) 1999-09-23 WO disclosed
US-5942555-A Photoactivatable chain transfer agents and semi-telechelic photoactivatable polymers prepared therefrom SURMODICS, INC. (US) 1999-08-24 US disclosed
WO-1999016907-A2 REAGENT AND METHOD FOR ATTACHING TARGET MOLECULES TO A SURFACE SURMODICS, INC. (US) 1999-04-08 WO disclosed
US-5858653-A Reagent and method for attaching target molecules to a surface SURMODICS, INC. (US) 1999-01-12 US disclosed
EP-0888389-A1 PHOTOACTIVATABLE CHAIN TRANSFER AGENTS SurModics, Inc. (US) 1999-01-07 EP disclosed
WO-1997034935-A1 PHOTOACTIVATABLE CHAIN TRANSFER AGENTS BSI CORPORATION (US) 1997-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052460-A1 Latent reactive blood compatible agents FGB, HLA-A, HLA-C SRD5A2 2715/4885ALDH1A1 530/4885HTT 3760/4885
US-20050170427-A1 Target molecule attachment to surfaces EPCAM, PCNA, POLM SRD5A2 4721/4885ALDH1A1 1754/4885HTT 4523/4885
US-20070082022-A1 LATENT REACTIVE BLOOD COMPATIBLE AGENTS FGB, HLA-A, HLA-C SRD5A2 2715/4885ALDH1A1 530/4885HTT 3760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.